DeepMind Pitches AI to Solve Disease Over 20 Years as Google I/O Claim Draws Scrutiny
Updated
Updated · The Verge · May 20
DeepMind Pitches AI to Solve Disease Over 20 Years as Google I/O Claim Draws Scrutiny
5 articles · Updated · The Verge · May 20
Demis Hassabis told Google I/O that DeepMind wants to “reimagine” drug discovery with the long-term goal of solving all disease, a sweeping claim tied to its Gemini for Science research tools.
20 years or more is a more realistic horizon, the report says, because AI can speed discovery but cannot bypass clinical trials, animal testing, regulatory review, or other established scientific safeguards.
AlphaFold and AlphaGenome underpin that pitch: AlphaFold has helped researchers study protein structures linked to malaria vaccines, LDL cholesterol and early-onset Parkinson’s, while AlphaGenome aims to predict DNA mutations but still has major limits.
AI already helped shorten Covid-19 vaccine development, yet ethical, privacy, bias and access concerns remain, underscoring that research gains do not translate into near-term cures for every disease.
The broader risk is that a soundbite like “solve all disease” can blur the line between researcher-focused tools and consumer AI health hype, feeding misleading expectations about what AI can actually deliver.
As AI promises to cure diseases, will it lead to affordable healthcare or a new era of medical inequality?
AI-designed drugs boast high success in early trials, so what’s the real bottleneck preventing their final approval?
If AI systems can be easily misled by false data, how can we trust them with critical health decisions?
Alphabet’s Isomorphic Labs Secures $2.1B to Launch AI-Designed Drugs in 2026 Human Trials
Overview
Isomorphic Labs, a spinout from Google DeepMind, is set to begin its first human clinical trials for AI-designed drugs in 2026, marking a major leap from predictive AI tools to advanced generative drug design. By leveraging platforms like AlphaFold, the company can model novel chemical structures and design synthetic proteins, opening new possibilities for cancer treatment and other diseases. Backed by a $2.1 billion Series B funding round and strong investor confidence, Isomorphic Labs demonstrates how AI is transforming drug discovery, accelerating the path from scientific breakthroughs to real-world clinical applications.